Search Result

No matches for "

55752

" within the MedChemExpress (MCE) catalog. Here are the results you might be looking for.

By Targets:	Amyloid-β (1) Beta-secretase (1) Calcium Channel (4) CTLA-4 (1) Drug Derivative (1) Endogenous Metabolite (1) Glucokinase (3) Isotope-Labeled Compounds (2) Leukotriene Receptor (1) MicroRNA (4) mTOR (2) PD-1/PD-L1 (1) Reactive Oxygen Species (ROS) (4) Reference Standards (2)
By Research Areas:	Cancer (7) Cardiovascular Disease (5) Infection (1) Inflammation/Immunology (3) Metabolic Disease (3) Neurological Disease (2)
Oligonucleotides:	miRNA mimics (1) miRNA antagomirs (1) miRNA agomirs (1) MicroRNAs (4) miRNA inhibitors (1)

Inhibitors & Agonists

Inhibitory Antibodies

Isotope-Labeled Compounds

Antibodies

Oligonucleotides

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-17402

Nisoldipine 2 Publications Verification BAY-k 5552	Calcium Channel Reactive Oxygen Species (ROS)	Infection Cardiovascular Disease Neurological Disease
Nisoldipine (BAY-k 5552; Sular) is an orally active and blood-brain barrier-penetrating dihydropyridine calcium antagonist, with greater vascular selectivity than other calcium channel antagonists. Nisoldipine inhibits calcium influx and blocks voltage-gated calcium channels. Nisoldipine dilates coronary and systemic arteries. Nisoldipine has antihypertensive and anti-anginal activity. Nisoldipine also displays neuroprotective and antiviral activity .

HY-109030

Dorzagliatin 3 Publications Verification HMS5552	Glucokinase	Metabolic Disease
Dorzagliatin (HMS5552), a dual-acting glucokinase (GK) activator, improves glycaemic control and pancreatic β-cell function in type 2 diabetes .

HY-132168

RMC-5552 5 Publications Verification	mTOR	Cancer
RMC-5552 is a potent and selective mTORC1 inhibitor. RMC-5552 inhibits phosphorylation of mTORC1 pS6K and p4EBP1 with IC₅₀s of 0.14 nM and 0.48 nM, respectively. RMC-5552 shows much lower pAKT inhibition (IC₅₀ of 19 nM), resulting in mTORC1/mTORC2 selectivity approaching 40-fold. RMC-5552 has anti-cancer activity .

HY-13769A

TPT-260 Dihydrochloride 2 Publications Verification NSC55712; TPU-260 Dihydrochloride	Drug Derivative Amyloid-β Beta-secretase	Cardiovascular Disease Neurological Disease Inflammation/Immunology
TPT-260 Dihydrochloride (NSC55712), a thiophene thiourea derivative, is a retromer complex stabilizer against thermal denaturation (K_d = ~5 µM). TPT-260 Dihydrochloride increases the levels of retromer proteins, shifts amyloid-precursor protein (APP) away from the endosome, and decreases the pathogenic processing of APP. TPT-260 Dihydrochloride inhibits TLR4 upregulation, IKKβ phosphorylation, NF-κB p65 nuclear translocation, and NLRP3 inflammasome formation. TPT-260 Dihydrochloride improves retromer-mediated cargo trafficking, reduces brain infarct area, and decreases amyloid plaque deposition. TPT-260 Dihydrochloride exhibits minimal cytotoxicity to primary microglia at tested concentrations. TPT-260 Dihydrochloride can be used for the research of inflammatory bowel disease, ischemic stroke and Alzheimer's disease .

HY-P990690

Volrustomig MEDI-5752	PD-1/PD-L1 CTLA-4	Cancer
Volrustomig (MEDI-5752) is a human IgG1 κ monoclonal antibody targeting CTLA4/PD1. The isotype control for Volrustomig is Human IgG1 kappa, Isotype Control (HY-P99001). Volrustomig anchors to the surface of T cells by binding PD-1, induces PD-1 internalization and degradation, and preferentially inhibits CTLA-4 on activated PD-1 ⁺ T cells. Volrustomig binds to tumor-infiltrating lymphocytes and a subset of PD-1 ⁺ B cells, enhances T cell function and IFNγ secretion. Volrustomig reduces the activation of non-tumor-infiltrating lymphocytes and exhibits manageable toxicity. Volrustomig can be used in research on various cancers, such as non-small cell lung cancer, gastric cancer, hepatobiliary cancer, and cervical cancer .

HY-134903

(32-Carbonyl)-RMC-5552	mTOR	Cancer
(32-Carbonyl)-RMC-5552 is a potent mTOR inhibitor. (32-Carbonyl)-RMC-5552 inhibits mTORC1 and mTORC2 substrate (p-P70S6K-(T389), p-4E-BP1-(T37/36), AND p-AKT1/2/3-(S473)) phosphorylation with pIC₅₀s of > 9, >9 and between 8 and 9, respectively (patent WO2019212990A1, example 2) .

HY-107607

*FPL-55712* free base**	Leukotriene Receptor	Inflammation/Immunology
FPL-55712 free base is a leukotriene receptor antagonist. FPL-55712 free base is also an antagonist of slow reacting substance of anaphylaxis (*SRS-A). FPL-55712* free base inhibits leukotriene-induced bronchoconstriction .**

HY-109030R

Dorzagliatin (Standard) HMS5552 (Standard)	Reference Standards Glucokinase	Metabolic Disease
Dorzagliatin (Standard) is the analytical standard of Dorzagliatin. This product is intended for research and analytical applications. Dorzagliatin (HMS5552), a dual-acting glucokinase (GK) activator, improves glycaemic control and pancreatic β-cell function in type 2 diabetes .

HY-107607A

FPL-55712	Endogenous Metabolite	Inflammation/Immunology
FPL-55712 is a cysteine leukotriene type 1 receptor antagonist with anti-inflammatory activity. FPL-55712 can effectively block the biological response caused by leukotrienes, reduce allergic reactions and airway inflammation. FPL-55712 shows potential in suppressing asthma and allergic rhinitis .

HY-17402R

Nisoldipine (Standard) BAY-k 5552 (Standard)	Reference Standards Calcium Channel Reactive Oxygen Species (ROS)	Cardiovascular Disease
Nisoldipine (Standard) is the analytical standard of Nisoldipine. This product is intended for research and analytical applications. Nisoldipine (BAY-k 5552; Sular) is a highly efficient and specific L-type Cav1.2 channel blocker with an IC50 of 10 nM.

HY-RI01723A

*hsa-miR-5572* antagomir**	MicroRNA	Cancer
hsa-miR-5572 antagomirs are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA antagomirs have 2 phosphorothioates at the 5' end, 4 phosphorothioates at the 3' end, 1 cholesterol group at the 3' end, and full-length nucleotide 2'-methoxy modification. The miRNA antagomirs strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning. Stability of miRNA antagomirs appears to be significantly higher than miRNA inhibitors, they exhibits enhanced cellular uptake, stability and regulatory activity in vivo.

hsa-miR-5572 antagomir hsa-miR-5572 antagomir

HY-R01723

*hsa-miR-5572* mimic**	MicroRNA	Cancer
hsa-miR-5572 mimics are small, chemically synthesized double-stranded RNAs that mimic endogenous miRNAs and enable miRNA functional analysis by up-regulation of miRNA activity.

hsa-miR-5572 mimic hsa-miR-5572 mimic

HY-17402S

Nisoldipine-d6 BAY-k 5552-d₆	Isotope-Labeled Compounds Calcium Channel Reactive Oxygen Species (ROS)	Cardiovascular Disease
Nisoldipine-d₆ is the deuterium labeled Nisoldipine. Nisoldipine(BAY-k 5552; Sular) is a calcium channel blocker belonging to the dihydropyridines class, specific for L-type Cav1.2 with an IC50 of 10 nM.

HY-17402S3

Nisoldipine-d3 BAY-k 5552-d₃	Calcium Channel Reactive Oxygen Species (ROS) Isotope-Labeled Compounds	Cardiovascular Disease
Nisoldipine-d₃ is deuterated labeled Nisoldipine (HY-17402). Nisoldipine (BAY-k 5552; Sular) is a highly efficient and specific L-type Cav1.2 channel blocker with an IC50 of 10 nM.

HY-119813

(S,S)-Sinogliatin (S,S)-HMS-5552; (S,S)-RO-5305552	Glucokinase	Metabolic Disease
(S,S)-Sinogliatin ((S,S)-HMS-5552) is the (S,S) -enantiomer of Sinogliatin. Sinogliatin is a glucokinase activator that can be used to study type 2 diabetes .

HY-R01723A

*hsa-miR-5572* agomir**	MicroRNA	Cancer
hsa-miR-5572 agomirs are chemically-modified double-strand miRNA mimics with modified mature miRNA strand: 2 phosphorothioates at the 5' end, 4 phosphorothioates at the 3' end, 3' end cholesterol group, and full-length nucleotide 2'-methoxy modification. They are designed to mimic endogenous miRNAs and recommended for miRNA functional studies. Compared with miRNA mimics, they exhibits enhanced cellular uptake, stability and regulatory activity in vivo.

hsa-miR-5572 agomir hsa-miR-5572 agomir

HY-RI01723

*hsa-miR-5572* inhibitor**	MicroRNA	Cancer
hsa-miR-5572 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.

hsa-miR-5572 inhibitor hsa-miR-5572 inhibitor

Cat. No.	Product Name	Target	Research Area	Image

HY-P990690

Volrustomig MEDI-5752	PD-1/PD-L1 CTLA-4	Cancer
Volrustomig (MEDI-5752) is a human IgG1 κ monoclonal antibody targeting CTLA4/PD1. The isotype control for Volrustomig is Human IgG1 kappa, Isotype Control (HY-P99001). Volrustomig anchors to the surface of T cells by binding PD-1, induces PD-1 internalization and degradation, and preferentially inhibits CTLA-4 on activated PD-1 ⁺ T cells. Volrustomig binds to tumor-infiltrating lymphocytes and a subset of PD-1 ⁺ B cells, enhances T cell function and IFNγ secretion. Volrustomig reduces the activation of non-tumor-infiltrating lymphocytes and exhibits manageable toxicity. Volrustomig can be used in research on various cancers, such as non-small cell lung cancer, gastric cancer, hepatobiliary cancer, and cervical cancer .

Cat. No.	Product Name	Chemical Structure

HY-17402S

Nisoldipine-d6
Nisoldipine-d₆ is the deuterium labeled Nisoldipine. Nisoldipine(BAY-k 5552; Sular) is a calcium channel blocker belonging to the dihydropyridines class, specific for L-type Cav1.2 with an IC50 of 10 nM.

HY-17402S3

Nisoldipine-d3
Nisoldipine-d₃ is deuterated labeled Nisoldipine (HY-17402). Nisoldipine (BAY-k 5552; Sular) is a highly efficient and specific L-type Cav1.2 channel blocker with an IC50 of 10 nM.

Host:	Mouse (4)
Reactivity:	Human (4) Rat (3) Mouse (3) Monkey (1)
Application:	IHC-P (3) ICC/IF (4) WB (3) ELISA (4)
Isotype:	IgG (1) IgG1 (2) IgG2b (1)
Conjugation:	Non-conjugated (4)
Clonality:	Monoclonal (4)
Modification:	Unmodified (4)

Cat. No.	Compare	Product Name	Application	Reactivity	Image

HY-P86060

	Humanm Placental lactogen Antibody (YA5752)	IHC-P, ICC/IF, ELISA	Human
	Humanm Placental lactogen Antibody (YA5752) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to Humanm Placental lactogen.

HY-P85860

	c-Myc Antibody (YA5552) Myc proto-oncogene protein; Class E basic helix-loop-helix protein 39; bHLHe39; Proto-oncogene c-Myc; Transcription factor p64;	IHC-P, WB, ICC/IF, ELISA	Human, Mouse, Rat
	c-Myc Antibody (YA5552) is a Mouse-derived and non-conjugated IgG2b monoclonal antibody, targeting to c-Myc.

HY-P85883

	Met（c-Met） Antibody (YA5575) MET; Hepatocyte growth factor receptor; HGF receptor; HGF/SF receptor; Proto-oncogene c-Met; Scatter factor receptor; SF receptor; Tyrosine-protein kinase Met	WB, ICC/IF, ELISA	Human, Mouse, Rat, Monkey
	Met（c-Met） Antibody (YA5575) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to Met（c-Met）.

HY-P85880

	Chromogranin A Antibody (YA5572) beta Granin antibody; betagranin; N-terminal fragment of chromogranin A; antibody; catestatin antibody; CgA antibody; CHG A antibody; Chga antibody; chromofungin antibody; Chromogranin A antibody; Chromogranin A parathyroid secretory protein 1 antibody; Chromogranin A precursor antibody; ChromograninA antibody; CMGA_HUMAN antibody; ER-37 antibody; Pancreastatin antibody; Parastatin antibody; Parathyroid secretory protein 1 antibody; Pituitary secretory protein I antibody; Secretory protein I antibody; SP I antibody; SP-I antibody; SP1 antibody; SPI antibody; vasostatin 2 antibody; Vasostatin antibody; Vasostatin I antibody; Vasostatin II antibody; vasostatin-2 antibody;	IHC-P, WB, ICC/IF, ELISA	Human, Mouse, Rat
	Chromogranin A Antibody (YA5572) is a Mouse-derived and non-conjugated IgG monoclonal antibody, targeting to Chromogranin A.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Host
Reactivity
Application
Dilution Ratio
Molecular Weight
Conjugation
Clonality
Immunogen
Appearance
Isotype
Gene ID
SwissProt ID
Purity
Formulation
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Product Name		Classification

HY-RI01723A

*hsa-miR-5572* antagomir**		MicroRNAs miRNA antagomirs
hsa-miR-5572 antagomirs are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA antagomirs have 2 phosphorothioates at the 5' end, 4 phosphorothioates at the 3' end, 1 cholesterol group at the 3' end, and full-length nucleotide 2'-methoxy modification. The miRNA antagomirs strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning. Stability of miRNA antagomirs appears to be significantly higher than miRNA inhibitors, they exhibits enhanced cellular uptake, stability and regulatory activity in vivo.

HY-R01723

*hsa-miR-5572* mimic**		MicroRNAs miRNA mimics
hsa-miR-5572 mimics are small, chemically synthesized double-stranded RNAs that mimic endogenous miRNAs and enable miRNA functional analysis by up-regulation of miRNA activity.

HY-R01723A

*hsa-miR-5572* agomir**		MicroRNAs miRNA agomirs
hsa-miR-5572 agomirs are chemically-modified double-strand miRNA mimics with modified mature miRNA strand: 2 phosphorothioates at the 5' end, 4 phosphorothioates at the 3' end, 3' end cholesterol group, and full-length nucleotide 2'-methoxy modification. They are designed to mimic endogenous miRNAs and recommended for miRNA functional studies. Compared with miRNA mimics, they exhibits enhanced cellular uptake, stability and regulatory activity in vivo.

HY-RI01723

*hsa-miR-5572* inhibitor**		MicroRNAs miRNA inhibitors
hsa-miR-5572 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.

Inquiry Online

Submit your filled information, we will contact you soon.

Salutation:		* Country or Region:
* Applicant Name:		* Organization Name:
* Department:
* Email Address:		* Product Name:
Cat. No.:		* Requested quantity:
* Phone Number:
MCE Japan Authorized Agent:	ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Remarks:

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: